來寶網Logo

熱門詞:生物顯微鏡 水質分析儀 微波消解 熒光定量PCR 電化學工作站 生物安全柜

現在位置首頁>技術資料首頁>行業動態>公司動態>GE Healthcare并購Whatman plc Whatman is now part of GE Healthcare

GE Healthcare并購Whatman plc Whatman is now part of GE Healthcare

GE Healthcare2010年12月24日 9:57 點擊:3233

 
通用(GE)醫療集團GE Healthcare Life Sciences    英國沃特曼Whatman

Whatman is now part of GE Healthcare, creating a centre of excellence in separation technology.
1月份曾傳言有4路買家競相出價收購過濾、分離技術專家——英國沃特曼公司(Whatman plc),就在此傳聞抬升Whatman的疲弱股價之后,隸屬于通用電氣公司(General Electric Co)、并專注于生命科學和醫療業務的通用電氣醫療集團(GE Healthcare Ltd)脫穎而出,醞釀收購Whatman,其出價大約為3.63億英鎊(7.18億美元,其匯率0.51英鎊= 1美元),折合每股2.70英鎊。雙方談妥的價格低于去年春天高峰期的估價,當時股價的記錄僅僅低于每股3.00英鎊,但是卻比去年的12月份低1.74英鎊的高額股票溢價。

此次收購將遵循英國法律的“協議計劃”,所有Whatman公司董事已批準將公司其股份出售給GE Healthcare,包括其最大股東——英國倫敦的赫米斯焦點資產管理公司(Hermes Focus Asset Management Ltd)。Whatman主席Michael Harper先生評論說,在過去幾個月里,公司一直在與潛在的收購者進行商談。表示有收購意向的其他公司有:丹納赫集團(Danaher)、密理博公司(Millipore)與派克漢尼汾公司(Parker Hanifin)。

GE Healthcare生命科學部總裁Peter Ehrenheim先生表示:這兩家公司結合“非常適合”, 帶來的新技術將有力地幫助研究人員進一步理解基因和蛋白質在人類疾病中扮演的角色。Enrenheim先生進一步談道:Whatman的“過濾組合”極大地拓展了GE Healthcare以前沒有涉及到的基于實驗室耗材配件的市場領域。“不過,對我們來說特別感興趣的是基于濾紙的技術,如DNA交換、儲存技術產品——FTA卡,這可能成為個人醫療領域的一種重要方法”,他補充說道。

GE Healthcare在生命科學技術、特別是在蛋白質科學以及在生物制藥制造業市場地位方面的優勢,結合擁有270年悠久歷史的Whatman的精湛過濾技術,將有利于客戶在生物醫學和藥物發現的研究;Enrenheim先生進一步表示,GE Healthcare與Whatman的結合,沒有大的產品和市場的重疊。Whatman公司的首席執行官Kieran Murphy先生補充說道:“Whatman在制藥、診斷市場和法醫學領域上所具有的產品機會,將在GE Healthcare這種大環境中會有更大的成功機會。”

盡管Whatman被描述是一個“成功的、有利潤的企業”,上任近一年的Murphy先生于2007年9月宣布了一項戰略性調整計劃,包括公司運營績效管理、客戶服務和供應鏈方面的廣泛改變。Murphy先生說:這些改變,將包括一些制造業務部分的重組。Ehrenheim先生解釋說:“我們已經進入了拍賣程序,并為以這項戰略計劃為基礎的交易付出了代價,針對象Whatman這樣相對較小的公司來說,貫徹執行這樣的戰略調整也將有相當的風險。”

Whatman公司將成為GE Healthcare 生命科學部門下屬的一個獨立部門,同時前Whatman公司的首席執行官 Murphy先生將繼續留任。

GE Healthcare announces the acquisition of Whatman - sample preparation and filtration technologies experts. Whatman’s product offerings are highly complementary with GE Healthcare’s own Life Sciences business; combining the skills and knowledge of the two businesses will create significant added value for customers. GE Healthcare’s Life Sciences business is a world-class provider of technologies for cellular and protein science research, and is a key area of growth. Expanding our skill base and product offerings in this area supports the Early Health vision of aiding earlier diagnosis and treatment of diseases.

Whatman has key enabling technologies used in the understanding of gene and protein functions, with a reputation, based on a solid foundation of expertise, that will prove a great fit for GE Life Sciences business, as it brings new technologies fundamental to helping researchers increase their understanding of the role of genes and proteins in disease. Combining the skills of the two companies will enable GE Healthcare to create strong added value for customers in biomedical and drug discovery research.
 

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest.

GE Healthcare’s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological, and other conditions earlier. Our vision for the future is to enable a new “early health” model of care, focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a US$17 billion unit of General Electric Company (NYSE:GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com
 

About Whatman

A global leader in filtration technology, Whatman provides innovative life science products to the scientific community. Whatman has developed total sample preparation solutions through its robust line of filtration devices and membranes. The company’s breakthrough protein array technology and FTA® technology to capture, archive and purify DNA at room temperature enables it to provide novel solutions for the analytical, healthcare and bioscience markets. For more information please visit www.whatman.com

(來源: GE Healthcare )


全年征稿 / 資訊合作

聯系郵箱:[email protected]

版權與免責聲明

  • 凡本網注明“來源:來寶網”的所有作品,版權均屬于來寶網,轉載請必須注明來寶網, http://www.vhyrck.live,違反者本網將追究相關法律責任。
  • 本網轉載并注明自其它來源的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點或證實其內容的真實性,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品來源,并自負版權等法律責任。
  • 如涉及作品內容、版權等問題,請在作品發表之日起一周內與本網聯系,否則視為放棄相關權利。


35选7开奖查询